Loading organizations...
§ Private Profile · Marche-en-famenne, Luxembourg, Belgium
Clinical-stage biopharmaceutical company developing antithrombotic therapies for thrombotic, inflammatory diseases & ICH.
Bioxodes is a clinical-stage biopharmaceutical company developing novel antithrombotics and therapies for thrombotic and inflammatory diseases, based in Gosselies, Belgium. The organization focuses on treatments derived from natural sources like tick saliva, advancing its lead drug candidate, BIOX-101, to prevent blood clots and reduce neuroinflammation in patients suffering from intracerebral hemorrhage. Operating with fewer than 50 employees, the enterprise has raised €37 million in total funding to support its ongoing Phase 2a clinical trials and research initiatives. Bioxodes is backed by a syndicate of institutional investors and public funds, including Vives Louvain Technology Fund, Wallonie Entreprendre, and Sambrinvest. The company recently secured an Orphan Drug Designation from the US Food and Drug Administration for its primary therapeutic candidate. Bioxodes was founded in 2013 by Edmond Godfroid as an academic spin-off from the Université libre de Bruxelles.
Bioxodes has raised $22.5M across 4 funding rounds.
Bioxodes has raised $22.5M in total across 4 funding rounds.
Bioxodes has raised $22.5M in total across 4 funding rounds.
Bioxodes's investors include Alain Parthoens, European Regional Development Fund, Walloon Region.
Bioxodes has raised $22.5M across 4 funding rounds. Most recently, it raised $6.4M Series A Extension in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 10, 2025 | $6.4M Series A Plus | Alain Parthoens | — | Announced |
| Feb 12, 2025 | $3.1M Series A Plus | — | — | Announced |
| Nov 21, 2023 | $9.4M Series A | — | — | Announced |
| Nov 26, 2013 | $3.5M Seed | — | European Regional Development Fund, Walloon Region | Announced |